You are in the accessibility menu

Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCéspedes-Cruz, A.-
dc.contributor.authorGutiérrez-Suárez, R.-
dc.contributor.authorPistorio, A.-
dc.contributor.authorRavelli, A.-
dc.contributor.authorLoy, A.-
dc.contributor.authorMurray, K. J.-
dc.contributor.authorGertoni, V.-
dc.contributor.authorWulffraat, N.-
dc.contributor.authorOliveira, S.-
dc.contributor.authorWalsh, J.-
dc.contributor.authorCalvo Penades, I.-
dc.contributor.authorAlpigiani, M. G.-
dc.contributor.authorLahdenne, P.-
dc.contributor.authorSaad-Magalhães, C.-
dc.contributor.authorCortis, E.-
dc.contributor.authorLepore, L.-
dc.contributor.authorKimura, Y.-
dc.contributor.authorWouters, C.-
dc.contributor.authorMartini, A.-
dc.contributor.authorRuperto, N.-
dc.identifier.citationAnnals of the Rheumatic Diseases, v. 67, n. 3, p. 309-314, 2008.-
dc.description.abstractObjectives: To examine the change in health-related quality of life (HRQOL) and its determinants in children with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). Methods: Patients were extracted from the PRINTO clinical trial which aimed to evaluate the efficacy and safety profile of MTX administered in standard, intermediate or higher doses (10, 15 and 30 mg/m2/week respectively). Children with polyarticular-course JIA, who were less than 18 years and had a complete HRQOL assessment were included. Results: A total of 521 children were included. At baseline, patients with JIA showed poorer HRQOL (p<0.01) than healthy children. In 207/412 (50%) and 63 (15%) children, HRQOL values were 2 standard deviations below the mean of healthy controls in the physical and psychosocial summary scale, respectively. After 6 months of treatment with standard dose MTX, there was a statistically significant improvement in all HRQOL health concepts, particularly the physical ones. Similar improvements were observed in those who did not respond to a standard dose of MTX and were subsequently randomised to a higher dose. The presence of marked disability at baseline was associated with a fivefold increased risk of retaining poor physical health after 6 months of active treatment with standard dose MTX. Other less important determinants of retaining poor physical well-being were the baseline level of systemic inflammation, pain intensity and an antinuclear-antibody-negative status. Conclusions: MTX treatment produces a significant improvement across a wide range of HRQOL components, particularly in the physical domains, in patients with JIA.en
dc.subjectchild care-
dc.subjectclinical feature-
dc.subjectclinical trial-
dc.subjectcontrolled clinical trial-
dc.subjectcontrolled study-
dc.subjectdisease severity-
dc.subjectdose response-
dc.subjectdrug dose comparison-
dc.subjectdrug response-
dc.subjecterythrocyte sedimentation rate-
dc.subjectfunctional status-
dc.subjectjuvenile rheumatoid arthritis-
dc.subjectmajor clinical study-
dc.subjectpriority journal-
dc.subjectquality of life-
dc.subjectrandomized controlled trial-
dc.subjectscoring system-
dc.subjecttreatment outcome-
dc.subjectAntirheumatic Agents-
dc.subjectArthritis, Juvenile Rheumatoid-
dc.subjectChild, Preschool-
dc.subjectDisability Evaluation-
dc.subjectDose-Response Relationship, Drug-
dc.subjectImmunosuppressive Agents-
dc.subjectQuality of Life-
dc.subjectRecovery of Function-
dc.subjectSeverity of Illness Index-
dc.subjectTreatment Outcome-
dc.titleMethotrexate improves the health-related quality of life of children with juvenile idiopathic arthritisen
dc.contributor.institutionServizio di Epidemiologia e Biostatistica-
dc.contributor.institutionUniversità degli Studi-
dc.contributor.institutionRheumatology Department-
dc.contributor.institutionIstituto Gaetano Pini-
dc.contributor.institutionWilhelmina Kinderziekenhuis-
dc.contributor.institutionRoyal Alexandra Hospital-
dc.contributor.institutionHospital Universitario La Fe-
dc.contributor.institutionClinica Pediatrica-
dc.contributor.institutionPediatric Rheumatology-
dc.contributor.institutionOspedale Pediatrico Bambin Gesù-
dc.contributor.institutionUniversita' degli Studi di Trieste-
dc.contributor.institutionHackensack Medical Center-
dc.contributor.institutionUniversity Hospital Gasthuisberg-
dc.contributor.institutionCentro Medico Nacional La Raza-
dc.contributor.institutionHospital General de México-
dc.contributor.institutionInstituto de Puericultura e Pediatria Martagao Gesteira-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationIRCCS G Gaslini Pediatria II PRINTO, Genova-
dc.description.affiliationIRCCSG Gaslini Servizio di Epidemiologia e Biostatistica, Genova-
dc.description.affiliationIRCCS G Gaslini Pediatria II Università degli Studi, Genova-
dc.description.affiliationFRACP Princess Margaret Hospital for Children Rheumatology Department, Perth, WA-
dc.description.affiliationIstituto Gaetano Pini, Milan-
dc.description.affiliationWilhelmina Kinderziekenhuis Department of Pediatric Immunology and Rheumatology, Utrecht-
dc.description.affiliationRoyal Alexandra Hospital, Glasgow-
dc.description.affiliationHospital Universitario La Fe, Valencia-
dc.description.affiliationIRCCS G Gaslini Clinica Pediatrica, Genova-
dc.description.affiliationHospital for Children and Adolescents Helsinki University Central Hospital Pediatric Rheumatology, Helsinki-
dc.description.affiliationOspedale Pediatrico Bambin Gesù, Rome-
dc.description.affiliationUniversita' degli Studi di Trieste, Trieste-
dc.description.affiliationHackensack Medical Center, Hackensack, NJ-
dc.description.affiliationUniversity Hospital Gasthuisberg, Leuven-
dc.description.affiliationIRCCS G Gaslini Università di Genova PRINTO, Largo Gaslini, 5, 16147 Genova-
dc.description.affiliationCentro Medico Nacional La Raza, México City-
dc.description.affiliationResearch Division Hospital General de México, México City-
dc.description.affiliationInstituto de Puericultura e Pediatria Martagao Gesteira, Rio de Janeiro-
dc.description.affiliationFaculdade de Medicina de Botucatu Universidade Estadual Paulista, Botucatu-
dc.description.affiliationUnespFaculdade de Medicina de Botucatu Universidade Estadual Paulista, Botucatu-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofAnnals of the Rheumatic Diseases-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.